CU Cancer Center News and Stories

Pediatric osteosarcoma patients who are Hispanic or live in areas of high language isolation are more likely to have metastatic disease at the time of diagnosis, recently publish research shows.

Rachel Sauer | March 17, 2023

University of Colorado Cancer Center members Michael Leibowitz, MD, PhD, and Dan Regan, DVM, PhD, have received an $800,000 grant from the V Foundation for Cancer Research, co-founded by ESPN and legendary basketball coach Jim Valvano, to study a new potential treatment for pediatric osteosarcoma that spreads to the lungs. 

Greg Glasgow | February 23, 2023

Video Transcript:

Good morning, I’m Dr. Breelyn Wilky from the sarcoma program at the University of Colorado Cancer Center.

Cancer Center | July 01, 2020

When prostate cancer spreads, it most often spreads to bone. And while the 5-year survival rate for prostate cancer that has not spread is nearly 100 percent, once the disease reaches bone, the 5-year survival rate is only 29 percent. Now a University of Colorado Cancer Center study published in the Journal for Immunotherapy of Cancer suggests a new approach, or, possibly two new approaches against these bone metastases: While targeted therapies and anti-cancer immunotherapies have not been especially successful against primary prostate cancers, the study suggests that both these approaches may be effective against the bone metastases that grow from primary prostate cancers, and, in fact, the type of bone metastasis may dictate which targeted therapies and immunotherapies work best.

Cancer Center | December 02, 2019